Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER

被引:128
作者
Karlson, Bjorn W. [1 ,2 ]
Wiklund, Olov [2 ]
Palmer, Michael K. [3 ]
Nicholls, Stephen J. [4 ]
Lundman, Pia [5 ]
Barter, Philip J. [6 ]
机构
[1] AstraZeneca Gothenburg, Pepparedsleden 1, SE-43183 Molndal, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, SE-41345 Gothenburg, Sweden
[3] Manchester Metropolitan Univ, Sch Healthcare Sci, Manchester, Lancs, England
[4] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[5] Karolinska Inst, Danderyd Hosp, Stockholm, Sweden
[6] Univ New South Wales, Ctr Vasc Res, Sydney, NSW, Australia
关键词
Atorvastatin; Low-density lipoprotein cholesterol; Rosuvastatin; Simvastatin; Variability; METAANALYSIS; STATINS;
D O I
10.1093/ehjcvp/pvw006
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Aims Patient response to statin treatment is individual and varied. As a consequence, when using a specific-dose approach, as recommended in the 2013 American College of Cardiology/American Heart Association guideline, there will be a range of reductions in the concentration of low-density lipoprotein cholesterol (LDL-C). The aim of this study was to use individual patient data from the VOYAGER meta-analysis to determine the extent of the variability in LDL-C reduction in response to treatment across the recommended doses of different statins. Methods and results The percentage change from baseline in LDL-C was calculated using individual subject data collected from 32 258 patients treated with atorvastatin 10-80 mg, rosuvastatin 5-40 mg, or simvastatin 10-80 mg. The percentage change in LDL-C for each patient was then used to generate waterfall plots that demonstrated the extent of the variability in response to treatment at all doses of the three statins. The standard deviation of LDL-C reduction for all statins and doses ranged from 12.8 to 17.9%. The percentage of patients experiencing a suboptimal response (<30% reduction in LDL-C) ranged from 5.3 to 53.3%. Conclusion These results indicate that there is considerable individual variation in the LDL-C reduction at all doses of simvastatin, atorvastatin, and rosuvastatin.
引用
收藏
页码:212 / 217
页数:6
相关论文
共 8 条
[1]
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials [J].
Boekholdt, S. Matthijs ;
Hovingh, G. Kees ;
Mora, Samia ;
Arsenault, Benoit J. ;
Amarenco, Pierre ;
Pedersen, Terje R. ;
LaRosa, John C. ;
Waters, David D. ;
DeMicco, David A. ;
Simes, R. John ;
Keech, Antony C. ;
Colquhoun, David ;
Hitman, Graham A. ;
Betteridge, John ;
Clearfield, Michael B. ;
Downs, John R. ;
Colhoun, Helen M. ;
Gotto, Antonio M., Jr. ;
Ridker, Paul M. ;
Grundy, Scott M. ;
Kastelein, John J. P. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (05) :485-494
[2]
To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis [J].
Karlson, Bjorn W. ;
Palmer, Michael K. ;
Nicholls, Stephen J. ;
Lundman, Pia ;
Barter, Philip J. .
ATHEROSCLEROSIS, 2015, 241 (02) :450-454
[3]
Masson M, 2014, REV ARGENT CARDIOL, V82, P34, DOI [10.7775/rac.es.v82.i1.2882, DOI 10.7775/RAC.ES.V82.I1.2882]
[4]
Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER) [J].
Nicholls, Stephen J. ;
Brandrup-Wognsen, Gunnar ;
Palmer, Mike ;
Barter, Philip J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (01) :69-76
[5]
Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner [J].
Pedro-Botet, J ;
Schaefer, EJ ;
Bakker-Arkema, RG ;
Black, DM ;
Stein, EM ;
Corella, D ;
Ordovas, JM .
ATHEROSCLEROSIS, 2001, 158 (01) :183-193
[6]
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J].
Stone, Neil J. ;
Robinson, Jennifer G. ;
Lichtenstein, Alice H. ;
Merz, C. Noel Bairey ;
Blum, Conrad B. ;
Eckel, Robert H. ;
Goldberg, Anne C. ;
Gordon, David ;
Levy, Daniel ;
Lloyd-Jones, Donald M. ;
McBride, Patrick ;
Schwartz, J. Sanford ;
Shero, Susan T. ;
Smith, Sidney C., Jr. ;
Watson, Karol ;
Wilson, Peter W. F. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (25) :2889-2934
[7]
Statins Personalized [J].
Superko, H. Robert ;
Momary, Kathryn M. ;
Li, Yonghong .
MEDICAL CLINICS OF NORTH AMERICA, 2012, 96 (01) :123-+
[8]
A systematic review and meta-analysis on the therapeutic equivalence of statins [J].
Weng, T. -C. ;
Yang, Y. -H. Kao ;
Lin, S. -J. ;
Tai, S. -H. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (02) :139-151